Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

COVID-19's hidden toll on diabetic organs revealed

NCT ID NCT04805970

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at organ changes in people recovering from COVID-19, comparing those with and without type 2 diabetes. Researchers will use scans to measure organ size and volume. The goal is to learn more about how COVID-19 affects the body long-term in diabetic patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand how COVID-19 affects organs in people with diabetes, potentially guiding future care.
What could go wrong
This is a small observational study with only 35 participants, so findings may not apply to everyone. It does not test any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

35 people

The number who actually took part.

Started

Mar 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who were initially hospitalized with laboratory-confirmed SARS-CoV-2 infection \[COVID-19 disease\], who are no-longer considered infectious by approved bioassay

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For Type 2 Diabetes (T2D) 1. Male or female 18 years of age and older willing and able to give informed consent to participate in the study 2. Confirmed diagnosis of SARS-CoV-2 RNA via a polymerase chain reaction (PCR) assay (having been discharged at least 2 months from hospital but not greater than 6 months). 3. Diagnosis of T2D according to American Diabetes Association (ADA) criteria. 4. Must have access to a computer/laptop or a modern (no more than 3-4 years old) smart phone/tablet for cognitive assessments. For participant without Type 2 Diabetes (T2D) 1. Male or female 18 years of age and older willing and able to give informed consent to participate in the study 2. Confirmed diagnosis of SARS-CoV-2 RNA via a polymerase chain reaction (PCR) assay (having been discharged at least 2 months from hospital but not greater than 6 months). 3. Must have access to a computer/laptop or a modern (no more than 3-4 years old) smart phone/tablet for cognitive assessments. Exclusion Criteria: 1. Symptoms of active respiratory viral infection: 1. high temperature (over 37.8°C/100.4°F) 2. cough (consistent for over an hour; 3 or more episodes in 24 hours) 2. Any history of Type I diabetes 3. The participant may not enter the study with any known contraindication to magnetic resonance imaging including 1. Pregnancy, lactation or 6 months postpartum from the scheduled date of collection 2. Metal implants (pacemaker, aneurysm clips) based on Investigator's judgment at Screening 3. Unable to participate in MRI assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on Investigator's judgment at Screening 4. Unable to tolerate MRI imaging or claustrophobia 4. Any condition, including a significant underlying disease or disorder which, in the opinion of the investigator, may put the participant at risk by participating in the study or limit the participant's ability to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AdventHealth Translational Research Institute

    Orlando, Florida, 32804, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.